Home/Navrogen/Dr. Jeffrey V. Ravetch
DJ

Dr. Jeffrey V. Ravetch

Scientific Advisor (inferred)

Navrogen

Therapeutic Areas

Navrogen Pipeline

DrugIndicationPhase
NAV-001Solid Tumors (MSLN+), e.g., Lung Adenocarcinoma, MesotheliomaPreclinical
NAV-006Hematological Malignancies (CD20+), e.g., Non-Hodgkin’s LymphomaPreclinical
NAV-201Solid & Liquid CancersPreclinical
NAV-002Solid Tumors (FOLR1+)Preclinical
NAV-003Solid Tumors (MSLN+)Preclinical
NAV-004Solid TumorsPreclinical
NAV-005Solid & Liquid CancersPreclinical
NAV-205Solid & Liquid CancersPreclinical